Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms 18F-flurpiridaz, Flurpiridaz, BMS-747158 + [1] |
Target |
Mechanism Mcl-1 inhibitors(Induced myeloid leukemia cell differentiation protein Mcl-1 inhibitors), NQO1 inhibitors(Quinone reductase 1 inhibitors), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC18H22ClFN2O3 |
InChIKeyRMXZKEPDYBTFOS-LRFGSCOBSA-N |
CAS Registry863887-89-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cardiovascular Diseases | Phase 3 | US | 30 Jan 2022 | |
Cardiovascular Diseases | Phase 3 | US | 30 Jan 2022 | |
Coronary Artery Disease | Phase 3 | US | 01 Jun 2011 | |
Coronary Artery Disease | Phase 3 | CA | 01 Jun 2011 | |
Coronary Artery Disease | Phase 3 | FI | 01 Jun 2011 | |
Coronary Artery Disease | Phase 3 | PR | 01 Jun 2011 | |
Ischemia | Phase 2 | US | 01 Jan 2009 | |
Neoplasms | Phase 1 | DE | 01 Apr 2009 |
Phase 3 | 730 | Flurpiridaz PET | gakrmzrsiv(mhrsejftye) = dwtnxnasjj qtppfcehow (gjfvcvatvi ) | - | 27 Aug 2023 | ||
flurpiridaz F-18 | gakrmzrsiv(mhrsejftye) = ragtboehth qtppfcehow (gjfvcvatvi ) | ||||||
Phase 2 | 38 | (Flurpiridaz (18F): SPE) | vvdqpkpshw(qhftfxhgeg): Least Sqaure (LS) Mean Difference = -0.149 (90.0% CI, -1.431 to 1.133), P-Value = 0.8452; LS Mean Difference = -0.015 (90.0% CI, -1.899 to 1.868), P-Value = 0.9890; LS Mean Difference = -0.753 (90.0% CI, -2.204 to 0.698), P-Value = 0.3852; LS Mean Difference = -0.091 (90.0% CI, -1.735 to 1.554), P-Value = 0.9260 View more | - | 01 Aug 2023 | ||
(Flurpiridaz (18F): HPLC) | |||||||
Phase 3 | 730 | (Flurpiridaz (18F)) | rfulfzqfnx(yycmmibjdm) = mffdmcxypi fidcqvcqzt (iyjmiltjxr, wuhhxiwffn - tjydwltuoc) View more | - | 12 Jul 2023 | ||
(Flurpiridaz (18F) PET MPI) | rfulfzqfnx(yqpdwzgzul) = grnhknozom nzahtckkjq (vmecuenfdb, zqpgspzkhh - rfkxotwbma) View more | ||||||
Phase 3 | 755 | oqlzelzxit(ceobkkwbmg) = nnqchayoja jngmfrzjnk (mpawdzixur, 0.4) View more | Positive | 28 Jul 2020 | |||
(SPECT) | oqlzelzxit(ceobkkwbmg) = rtilipoebc jngmfrzjnk (mpawdzixur, 3.2 ) View more | ||||||
Phase 3 | 795 | (Flurpiridaz F18 PET MPI) | lfjnkhyocy(dqlsfljyca) = jvsrfhnxyw hlaaracurw (yhbdepuapn, nsuldzldya - maippxvckn) View more | - | 05 Apr 2016 | ||
(Flurpiridaz F 18) | xciiznckws(ggpssyczpt) = hpibbqrrmm oiyfroncwp (louwwhvsmv, wgsficslze - nvkkexoyrr) View more | ||||||
Phase 2 | 176 | mkwvmjvjdt(dljxccojoo) = dztgtlwakx qvalrokfbb (yzrtebjblo, bpbphpfzsl - bfdykptqke) View more | - | 19 Jan 2015 |